About Us
Committed to becoming an influential and innovative vaccine company in China
CuroVax is situated in Changzhou City, Jiangsu Province, China. Spanning a total area of 50,000 square meters, CuroVax facility boasts a substantial building area of 41,000 square meters, which includes a dedicated purification zone spanning 20,000 square meters. We process full-cycle capabilities to independently develop, manufacture and commercialize various vaccines. Our state-of-the-art facilities are equipped to the highest standards, featuring independent virus vaccine production workshops, R&D laboratories, quality control laboratories and animal experiment centers.
Adhering to the innovation-oriented mode of combining self-development and joint research, CuroVax has established a number of technical platforms, including large-scale mammalian cell culture, large-scale antigen purification, vaccine validation and quality research, as well as mRNA vaccine development. The technological capability is increasing and the R&D pipeline continues to expand.
Policy and News Update
Pre season talk about influenza vaccines: correct cognition without hesitation
Luwang, September 11th (Reporter Guan Xiaohui, Correspondent Li Chengxiu, Ma Jin) Influenza is an acute respiratory infectious disease caused by the influenza virus that poses a threat to human health. It is seasonal (commonly known as the "flu season") and can cause serious complications such as pneumonia, encephalitis, and even death in infants, young children, and the elderly. Therefore, outbreaks of COVID-19 are prone to occur in schools, kindergartens, and elderly care institutions. Although there was a nationwide outbreak of H1N1 influenza A from February to April this year, according to perennial epidemiological data in China, the southern and northern regions generally have a high incidence in winter and spring (November to February of the following year), and the areas south of the Yangtze River can also have a high incidence in summer. Therefore, we are currently in the pre flu season, which is the best time to receive influenza vaccines, especially for infants, young children, primary and secondary school students, the elderly, medical personnel, and entry-exit port staff. However, due to cognitive differences, some parents and vaccination populations have varying degrees of hesitation in vaccination, mostly suspecting the effective protection of the vaccine, followed by anxiety about vaccination safety. For this, let's talk about topics related to influenza vaccines together.
The 2nd one in China! Kexing EV71-CA16 Bivalent HFMD Vaccine Approved for Clinical Use
The 2nd one in China! Kexing EV71-CA16 Bivalent HFMD Vaccine Approved for Clinical Use
The most groundbreaking anti-cancer strategy of chimeric antigen receptor T-cell (CAR-T) therapy is to modify self-sourced T-cells so that they can more precisely target cancer cells. Globally, several CAR-T therapies have been approved, giving doctors a new weapon in the face of malignant tumours, especially haematological tumours, that they were previously unable to do anything about.
